Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Entresto
Entresto
Novartis files suit against IRA after blockbuster Entresto makes CMS' price negotiations list
Novartis files suit against IRA after blockbuster Entresto makes CMS' price negotiations list
Fierce Pharma
Novartis
legal
Inflation Reduction Act
CMS
drug pricing
Entresto
Flag link:
Novartis hits back at Entresto selection on Medicare list
Novartis hits back at Entresto selection on Medicare list
Pharmaphorum
Novartis
Entresto
drug pricing
Medicare
Flag link:
The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023
The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023
BioSpace
patent cliff
patents
Takeda
Vyvanse
Pfizer
Eraxis
JNJ
Stelara
Merck
Isentress
Eiger Pharmaceuticals
Zokinvy
Astellas
Myrbetriq
Novartis
Entresto
Amgen
Otzela
Flag link:
Novartis to appeal district court ruling on heart drug patent
Novartis to appeal district court ruling on heart drug patent
BioPharma Dive
Novartis
Entresto
patents
legal
Flag link:
Novartis' Entresto infringes on university patents, lawsuit claims
Novartis' Entresto infringes on university patents, lawsuit claims
Endpoints
Novartis
Entresto
legal
patents
Flag link:
Novartis petitions FDA to block 18 generic competitors for its megablockbuster heart drug until 2024
Novartis petitions FDA to block 18 generic competitors for its megablockbuster heart drug until 2024
Endpoints
Novartis
generics
Entresto
Flag link:
ACC 2021: Novartis looks for silver linings in Entrestro’s narrow loss to an ACE inhibitor in heart attack patients
ACC 2021: Novartis looks for silver linings in Entrestro’s narrow loss to an ACE inhibitor in heart attack patients
Fierce Pharma
ACC
Novartis
Entresto
heart failure
Flag link:
Novartis’ blockbuster heart med Entresto snags FDA approval in larger patient group
Novartis’ blockbuster heart med Entresto snags FDA approval in larger patient group
Fierce Pharma
Novartis
Entresto
heart failure
labeling
FDA
Flag link:
Novartis' heart failure med Entresto wins FDA panel backing for bigger patient group—but just how much bigger?
Novartis' heart failure med Entresto wins FDA panel backing for bigger patient group—but just how much bigger?
Fierce Pharma
Novartis
Entresto
heart failure
heart failure with preserved ejection fraction
Flag link:
ESC: Novartis' Entresto racks up a heart failure study win—but it's a mixed one
ESC: Novartis' Entresto racks up a heart failure study win—but it's a mixed one
Fierce Pharma
Novartis
Entresto
ESC
heart failure
Flag link:
Novartis' Entresto gains steam with cardiologists despite stinging heart failure trial flop
Novartis' Entresto gains steam with cardiologists despite stinging heart failure trial flop
Fierce Pharma
Novartis
Entresto
heart failure
cardiologists
Flag link:
AHA: Novartis hoping for second go at broader use with 'profound' Entresto subdata
AHA: Novartis hoping for second go at broader use with 'profound' Entresto subdata
Fierce Pharma
Novartis
AHA
Entresto
Flag link:
ESC: Novartis looks for the bright side in flopped Entresto heart failure study
ESC: Novartis looks for the bright side in flopped Entresto heart failure study
Fierce Pharma
Novartis
heart failure
Entresto
clinical trials
ESC
European Society of Cardiology
Flag link:
5 Reasons Novartis Shareholders Aren't Shaken
5 Reasons Novartis Shareholders Aren't Shaken
Yahoo/Motley Fool
Novartis
Zolgensma
FDA
shareholders
Entresto
Flag link:
Novartis heart drug fails trial, curbing growth prospects
Novartis heart drug fails trial, curbing growth prospects
Yahoo/Reuters
Novartis
heart failure
Entresto
clinical trials
Flag link:
American College of Cardiology Conference Roundup - day 1
American College of Cardiology Conference Roundup - day 1
CP Wire
American College of Cardiology
Novartis
Entresto
heart failure
Edwards Lifesciences
Apple
TAVR
wearables
clinical trials
Apple Watch
atrial fibrillation
Flag link:
American College of Cardiology Conference Roundup - day 1
American College of Cardiology
Novartis
Entresto
heart failure
Edwards Lifesciences
Apple
TAVR
wearables
clinical trials
Apple Watch
atrial fibrillation
Flag link:
Novartis builds its blockbuster case for Entresto, beating out a cheap ACE inhibitor in a head-to-head study
Novartis builds its blockbuster case for Entresto, beating out a cheap ACE inhibitor in a head-to-head study
Endpoints
Novartis
Entresto
Flag link:
Novartis (NVS) Q4 Earnings & Sales Top on Cosentyx, Entresto
Novartis (NVS) Q4 Earnings & Sales Top on Cosentyx, Entresto
NASDAQ.com
Novartis
earnings
Cosentyx
Entresto
Flag link:
One big Novartis takeaway from Entresto's slow start? Heart failure doesn't work like oncology
One big Novartis takeaway from Entresto's slow start? Heart failure doesn't work like oncology
Fierce Pharma
Novartis
Entresto
drug launches
heart failure
oncology
Flag link:
Pages
1
2
3
next ›
last »